All research
2026-07-06 PubMed

Ang-1-releasing RADA16 peptide coating modulates inflammation and suppresses smooth muscle proliferation

An Ang-1-releasing self-assembling peptide coating for inflammation modulation and suppression of smooth muscle proliferation.

Background

Post-stent implantation vascular complications, including impaired re-endothelialization and persistent inflammation, frequently lead to late-stage thrombosis and in-stent restenosis. Current approaches often fall short in simultaneously promoting healing and suppressing detrimental cell proliferation. Angiopoietin-1 (Ang-1) is a crucial regulatory molecule for vascular homeostasis, coordinating endothelial regeneration and vascular stabilization. Leveraging self-assembling peptides offers a promising avenue for targeted vascular therapy to address these complex issues.

Study Design

Researchers engineered a RADA16 peptide-based coating loaded with Ang-1 to mimic the unbound state of endogenous Ang-1. The study evaluated the coating's ability to modulate inflammatory responses, promote re-endothelialization, and accelerate vascular repair. They assessed sustained Ang-1 release, cytocompatibility, and effects on human umbilical vein endothelial cells (HUVECs) and smooth muscle cells (SMCs). Macrophage (MA) proliferation and pro-inflammatory cytokine secretion (IL-6, TNF-α) were also measured, alongside macrophage polarization towards the M2 phenotype.

Results

The Ang-1-loaded RADA16 coating demonstrated sustained Ang-1 release for more than 14 days, confirming its potential for prolonged therapeutic action. Both the plain peptide coating and the Ang-1-loaded version exhibited excellent cytocompatibility, indicating low toxicity.

The Ang-1 loaded coating significantly enhanced the growth and migration of human umbilical vein endothelial cells (HUVECs) while selectively inhibiting the proliferation of smooth muscle cells (SMCs). Furthermore, the coating effectively suppressed macrophage (MA) proliferation and reduced the secretion of pro-inflammatory cytokines, specifically interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Importantly, both the plain peptide coating and the Ang-1-loaded coating promoted the polarization of macrophages toward the M2 phenotype, which is crucial for inflammation resolution and tissue repair. These findings collectively show the Ang-1-loaded coating creates an immune-favorable microenvironment conducive to vascular repair.

Key Findings

  • RADA16 peptide coating enabled sustained Ang-1 release for more than 14 days.
  • Ang-1 loaded coating significantly enhanced HUVEC growth and migration.
  • Ang-1 loaded coating selectively inhibited SMC proliferation.
  • Coating suppressed macrophage proliferation and reduced IL-6 and TNF-α secretion.
  • Both coatings promoted macrophage polarization toward the M2 phenotype.

Why It Matters

This research offers a novel strategy to address critical post-stent complications by simultaneously promoting vascular healing and suppressing detrimental cell growth. For clinicians, an Ang-1-eluting stent coating could significantly reduce rates of in-stent restenosis and late-stage thrombosis, improving long-term patient outcomes. The ability to sustain Ang-1 release for over 14 days suggests a durable therapeutic effect, potentially reducing the need for repeat interventions. While currently an in-vitro study, this work lays the groundwork for developing next-generation stent technologies that actively modulate the immune microenvironment and accelerate vascular repair. Further preclinical animal studies are needed to validate efficacy and safety in vivo.


ang-1 rada16 self-assembling-peptide vascular-repair inflammation restenosis
Source: pubmed:42404037 · Ingested 2026-07-06 · Digest: gemini-2.5-flash